The global neoantigen malignancy immunotherapy industry is currently experiencing a turbulent period of advancement, fueled by remarkable progress in personalized medicine and a growing understanding of the immune more info system's capability in combating tumors. Predictions indicate a ongoing increase in the coming years, driven by experimental t